NCT02680041 - 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment | Biotech Hunter

Enrollment

221

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

November 1, 2017

Study Completion Date

November 1, 2017

Conditions

Prostate Cancer

Interventions

DRUG

18F-fluciclovine PET CT

Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment

Trial Locations (17)

10016

Manhattan Medical Research, New York

10029

Icahn School of Medicine at Mount Sinai, New York

19004

Urologic Consultants of SE Pennsylvania, Bala-Cynwyd

19104

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

32209

University of Florida, Jacksonville

40202

University of Louisville, Louisville

46202

Roudebush VA Medical Center, Indianapolis

60153

Loyola University Medical Center, Maywood

63110

Washington University School of Medicine, St Louis

84112

University of Utah, Huntsman Cancer Institute, Salt Lake City

90048

Cedars-Sinai Medical Center, Los Angeles

Tower Urology, Los Angeles

91010

City of Hope National Medical Center, Duarte

92123

Genesis Research, LLC, San Diego

08724

Coastal Urology Associates, Brick